Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity

Mitochondrion

Volumn 10, Issue 2, 2010, Pages 115-124

  Guillet, Virginie ^a,b   Chevrollier, Arnaud ^a,c   Cassereau, Julien ^a,c,d   Letournel, Franck ^b,c   Gueguen, Naïg ^a,c   Richard, Laurence ^e   Desquiret, Valérie ^a,c   Verny, Christophe ^a,b,c   Procaccio, Vincent ^a,c,d   Amati Bonneau, Patrizia ^a,c   Reynier, Pascal ^a,b,c   Bonneau, Dominique ^a,b,c  

^a INSERM   (France)

^b Universite d'Angers   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d CNRS   (France)

^e Département de Neurobiologie   (France)

Author keywords

Autosomal dominant optic atrophy; Ethambutol; Mitochondria; OPA1

Indexed keywords

CYTOCHROME C OXIDASE; DYNAMIN; ETHAMBUTOL; OPTIC ATROPHY 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOSOMAL DOMINANT OPTIC ATROPHY; CASE REPORT; CELL FUNCTION; CELL STRAIN; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; COUPLING FACTOR; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; FIBROBLAST CULTURE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUNG TUBERCULOSIS; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; SKIN FIBROBLAST;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; ELECTRON TRANSPORT COMPLEX IV; ETHAMBUTOL; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; GTP PHOSPHOHYDROLASES; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MUTATION; OPTIC NERVE DISEASES;

EID: 76049106543     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2009.11.004     Document Type: Article

References (47)

1. Alexander C., Votruba M., Pesch U.E., Thiselton D.L., Mayer S., Moore A., Rodriguez M., Kellner U., Leo-Kottler B., Auburger G., Bhattacharya S.S., and Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat. Genet. 26 (2000) 211-215
2. Amati-Bonneau P., Valentino M.L., Reynier P., Gallardo M.E., Bornstein B., Boissière A., Campos Y., Rivera H., de la Aleja J.G., Carroccia R., Iommarini L., Labauge P., Figarella-Branger D., Marcorelles P., Furby A., Beauvais K., Letournel F., Liguori R., La Morgia C., Montagna P., Liguori M., Zanna C., Rugolo M., Cossarizza A., Wissinger B., Verny C., Schwarzenbacher R., Martín M.A., Arenas J., Ayuso C., Garesse R., Lenaers G., Bonneau D., and Carelli V. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain 131 (2008) 338-351
3. Amati-Bonneau P., Milea D., Bonneau D., Chevrollier A., Ferré M., Guillet V., Gueguen N., Loiseau D., de Crescenzo M.A., Verny C., Procaccio V., Lenaers G., and Reynier P. OPA1-associated disorders: phenotypes and pathophysiology. Int. J. Biochem. Cell Biol. 41 (2009) 1855-1865
4. Barron G.J., Tepper L., and Iovine G. Ocular toxicity from ethambutol. Am. J. Ophthalmol. 77 (1974) 256-260
5. Belanger A.E., Besra G.S., Ford M.E., Mikusová K., Belisle J.T., Brennan P.J., and Inamine J.M. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. USA 93 (1996) 11919-11924
6. Boya P., Gonzalez-Polo R.A., Poncet D., Andreau K., Vieira H.L., Roumier T., Perfettini J.L., and Kroemer G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22 (2003) 3927-3936
7. Buyske D.A., Peets E., and Sterlin W. Pharmacological and biochemical studies on ethambutol in laboratory animals. Ann. NY Acad. Sci. 135 (1966) 711-725
8. Carelli V., Ross-Cisneros F.N., and Sadun A.A. Mitochondrial dysfunction as a cause of optic neuropathies. Prog. Retin. Eye Res. 23 (2004) 53-89
9. Carr R.E., and Henkind P. Ocular manifestations of ethambutol, Toxic amblyopia after administration of an experimental antituberculous drug. Arch. Ophtalmol. 67 (1962) 566-571
10. Chan R.Y., and Kwok A.K. Ocular toxicity of ethambutol. Hong Kong Med. J. 12 (2006) 56-60
11. Chevrollier A., Guillet V., Loiseau D., Gueguen N., de Crescenzo M.A., Verny C., Ferre M., Dollfus H., Odent S., Milea D., Goizet C., Amati-Bonneau P., Procaccio V., Bonneau D., and Reynier P. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann. Neurol. 63 (2008) 794-798
12. Chung H., Yoon Y.H., Hwang J.J., Cho K.S., Koh J.Y., and Kim J.G. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol. Appl. Pharmacol. 235 (2009) 163-170
13. Cole A., May P.M., and Williams D.R. Metal binding by pharmaceuticals. Part 1. Copper(II) and zinc(II) interactions following ethambutol administration. Agents Actions 11 (1981) 296-305
14. De Marinis M. Optic neuropathy after treatment with anti-tuberculous drugs in a subject with Leber's hereditary optic neuropathy mutation. J. Neurol. 248 (2001) 818-819
15. Delettre C., Lenaers G., Griffoin J.M., Gigarel N., Lorenzo C., Belenguer P., Pelloquin L., Grosgeorge J., Turc-Carel C., Perret E., Astarie-Dequeker C., Lasquellec L., Arnaud B., Ducommun B., Kaplan J., and Hamel C.P. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 26 (2000) 207-210
16. Dotti M.T., Plewnia K., Cardaioli E., Manneschi L., Rufa A., Alemà G., and Federico A. A case of ethambutol-induced optic neuropathy harbouring the primary mitochondrial LHON mutation at nt 11778. J. Neurol. 245 (1998) 302-303
17. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 (2005) 2767-2775
18. Esposito L.A., Melov S., Panov A., Cottrell B., and Wallace D.C. Mitochondrial disease in mouse results in increase oxidative stress. Proc. Natl. Acad. Sci. USA 96 (1999) 4820-4825
19. Forbes M., Kuck N.A., and Peets E.A. Effect of ethambutol on nucleic acid metabolism in mycobacterium smegmatis and its reversal by polyamines and divalent cations. J. Bacteriol. 89 (1965) 1299-1305
20. Frezza C., Cipolat S., Martins de Brito O., Micaroni M., Beznoussenko G.V., Rudka T., Bartoli D., Polishuck R.S., Danial N.N., De Strooper B., and Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126 (2006) 177-189
21. Gallagher M., Weinberg R., and Simpson M.V. Effect of the bacterial DNA gyrase inhibitors, novobiocin, nalidixic acid, and oxolinic acid, on oxidative phosphorylation. J. Biol. Chem. 261 (1986) 8604-8607
22. Henderson P.J., McGivan J.D., and Chappell J.B. The action of certain antibiotics on mitochondrial, erythrocyte and artificial phospholipid membranes. The role of induced proton permeability. Biochem. J. 111 (1969) 521-535
23. Heng J.E., Vorwerk C.K., Lessell E., Zurakowski D., Levin L.A., and Dreyer E.B. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest. Ophthalmol. Vis. Sci. 40 (1999) 190-196
24. Hwang J.M., Kim J., and Park S.S. Leber's hereditary optic neuropathy mutations in ethambutol-induced optic neuropathy. J. Neurol. 250 (2003) 87-89
25. Ikeda A., Ikeda T., Ikeda N., Kawakami Y., and Mimura O. Leber's hereditary optic neuropathy precipitated by ethambutol. Jpn. J. Ophthalmol. 50 (2006) 280-283
26. Jäättelä M., Candé C., and Kroemer G. Lysosomes and mitochondria in the commitment to apoptosis: a potential role for cathepsin D and AIF. Cell. Death Differ. 11 (2004) 135-136
27. Kroon A.M., and Van den Bogert C. Antibacterial drugs and their interference with the biogenesis of mitochondria in animal and human cells. Pharm. Weekbl. Sci. 5 (1983) 81-87
28. Lardy H.A., Johnson D., and McMurray W.C. Antibiotics as tools for metabolic studies I. A survey of toxic antibiotics in respiratory, phosphorylative and glycolytic systems. Arch. Biochem. Biophys. 78 (1958) 587-597
29. Lee E.J., Kim S.J., Choung H.K., Kim J.H., and Yu Y.S. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J. Neuroophthalmol. 28 (2008) 269-277
30. Lessell S. Histopathology of experimental ethambutol intoxication. Invest. Ophthalmol. Vis. Sci. 15 (1976) 765-769
31. Letournel F., Bocquet A., Perrot R., Dechaume A., Guinut F., Eyer J., and Barthelaix A. Neurofilament high molecular weight-green fluorescent protein fusion is normally expressed in neurons and transported in axons: a neuronal marker to investigate the biology of neurofilaments. Neuroscience. 137 (2006) 103-111
32. Loiseau D., Chevrollier A., Verny C., Guillet V., Gueguen N., Pou de Crescenzo M.A., Ferré M., Malinge M.C., Guichet A., Nicolas G., Amati-Bonneau P., Malthièry Y., Bonneau D., and Reynier P. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann. Neurol. 61 (2007) 315-323
33. 2+ in the regulation of energy metabolism. Dev. Neurosci. 15 (1993) 165-173
34. Newton B.A. Mechanisms of antibiotic action. Annu. Rev. Microbiol. 19 (1965) 209-240
35. Nochez Y., Arsene S., Gueguen N., Chevrollier A., Ferré M., Guillet V., Desquiret V., Toutain A., Bonneau D., Procaccio V., Amati-Bonneau P., Pisella P.J., and Reynier P. Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to a mitochondrial coupling defect. Mol. Vis. 15 (2009) 598-608
36. Olichon A., Baricault L., Gas N., Guillou E., Valette A., Belenguer P., and Lenaers G. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 278 (2003) 7743-7746
37. Pressman B.C. Ionophorous antibiotics as models for biological transport. Fed. Proc. 27 (1968) 1283-1288
38. Reed P.W., and Lardy H.A. Uncoupling and specific inhibition of phosphoryl transfer reactions in mitochondria by antibiotic A20668. J. Biol. Chem. 250 (1975) 3704-3708
39. Rigoulet M., Leverve X., Fontaine E., Ouhabi R., and Guérin B. Quantitative analysis of some mechanisms affecting the yield of oxidative phosphorylation: dependence upon both fluxes and forces. Mol. Cell. Biochem. 184 (1998) 35-52
40. Sadun A.A., and Wang M.Y. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year?. J. Neuroophthalmol. 28 (2008) 265-268
41. Shepherd R.G., Baughn C., Cantrall M.L., Goodstein B., Thomas J.P., and Wilkinson R.G. Structure-activity studies leading to ethambutol, a new type of antituberculous compound. Ann. NY Acad. Sci. 135 (1966) 686-710
42. Solecki T.J., Aviv A., and Bogden J.D. Effect of a chelating drug on balance and tissue distribution of four essential metals. Toxicology 31 (1984) 207-216
43. Vallat J.M., Magy L., Lagrange E., Sturtz F., Magdelaine C., Grid D., and Tazir M. Diagnostic value of ultrastructural nerve examination in Charcot-Marie-Tooth disease: two CMT 1B cases with pseudo-recessive inheritance. Acta Neuropathol. 113 (2007) 443-449
44. 2-induced apoptosis of alveolar type II cells. J. Cell. Biochem. 94 (2005) 433-445
45. Yoon Y.H., Jung K.H., Sadun A.A., Shin H.C., and Koh J.Y. Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol. Appl. Pharmacol. 162 (2000) 107-114
46. Yu-Wai-Man P., Griffiths P.G., Hudson G., and Chinnery P.F. Inherited mitochondrial optic neuropathies. J. Med. Genet. 46 (2009) 145-158
47. Zhang L., Ging N.C., Komoda T., Hanada T., Suzuki T., and Watanabe K. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 579 (2005) 6423-6427